Helicase 50 (DDX50): A Potential Drug Target and Biomarker for Positive Health Impact

Target Name: DDX50

NCBI ID: G79009

DDX50

Helicase 50 (DDX50): A Potential Drug Target and Biomarker for Positive Health Impact

Introduction

Helicase 50 (DDX50) is a protein that plays a crucial role in DNA replication and repair, ensuring the orderly transmission of genetic information from parents to their offspring. As an essential enzyme in the DNA replication process, Helicase 50 is overexpressed or deleted. May lead to the occurrence of genetic diseases. In recent years, studies have found that DDX50 is overexpressed in many tumor cells and is closely related to tumor occurrence, progression and treatment response. Therefore, studying the target of DDX50 in tumor treatment has important clinical significance. This article aims to explore the research prospects of DDX50 as a drug target or biomarker.

Function and structure of DDX50

DDX50 is a protein belonging to the DNA-dependent DNA polymerase (DNADP) family and is widely present in bacteria and archaea. In eukaryotes, DDX50 mainly exists in the nucleus, mitochondria and chloroplasts, playing a key role in DNA replication, repair and damage repair processes.

The molecular structure of DDX50 consists of two subunits: the N-terminal 伪-helix, the middle variable region, and the C-terminal 尾-sheet. Among them, the variable region is the key region for the function of DDX50. Its unique secondary domain and substrate binding ability enable DDX50 to recognize and bind different types of DNA templates.

Expression of DDX50 in tumors

Many studies have found that DDX50 is up-regulated in a variety of tumor cells, including lung cancer, breast cancer, prostate cancer, and ovarian cancer. The expression level of DDX50 is positively correlated with tumor size, aggressiveness, and treatment response.

Compared with normal cells, the DDX50 expression of tumor cells has the following characteristics:

1. Overexpression: The expression of DDX50 in tumor cells is significantly higher than that in normal cells, which may be closely related to the occurrence and development of tumors.

2. Expression pattern: The expression pattern of DDX50 in tumor cells is time-specific, that is, in the early stages of tumor development, DDX50 expression increases, then gradually decreases, but then increases again during treatment.

3. Tumor progression

Protein Name: DExD-box Helicase 50

The "DDX50 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX50 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets